SUPERNUS PHARMACEUTICALS INC. - COMMON STOCK
38.06
08-January-25 15:45:00
15 minutes delayed
Stocks
+0.63
+1.68%
Today's range
36.76 - 38.31
ISIN
N/A
Source
NASDAQ
-
Supernus Announces Second Quarter 2021 Financial Results
04 Aug 2021 15:09:33 By Nasdaq GlobeNewswire
-
Supernus to Host Second Quarter 2021 Financial Results Conference Call
22 Jul 2021 15:37:21 By Nasdaq GlobeNewswire
-
Supernus to Present at Jefferies Virtual Healthcare Conference
25 May 2021 07:30:00 By Nasdaq GlobeNewswire
-
24 May 2021 07:30:00 By Nasdaq GlobeNewswire
-
Supernus Announces First Quarter 2021 Financial Results
05 May 2021 15:01:00 By Nasdaq GlobeNewswire
-
Supernus Announces Paragraph IV ANDA Filing for XADAGO®
04 May 2021 19:49:10 By Nasdaq GlobeNewswire
-
Supernus to Host First Quarter 2021 Financial Results Conference Call
27 Apr 2021 16:44:01 By Nasdaq GlobeNewswire
-
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD
02 Apr 2021 15:58:32 By Nasdaq GlobeNewswire
-
Supernus to Present at Cowen Healthcare Conference
26 Feb 2021 08:00:00 By Nasdaq GlobeNewswire
-
Supernus Announces Fourth Quarter and Full Year 2020 Financial Results
25 Feb 2021 15:00:00 By Nasdaq GlobeNewswire
-
Supernus to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call
23 Feb 2021 08:00:00 By Nasdaq GlobeNewswire
-
Supernus Resubmits New Drug Application for SPN-812 for the Treatment of ADHD in Pediatric Patients
08 Feb 2021 08:00:00 By Nasdaq GlobeNewswire
-
Supernus to Present at J.P. Morgan 39th Annual Healthcare Conference
06 Jan 2021 16:29:08 By Nasdaq GlobeNewswire